Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcellx, Inc. stock logo
ACLX
Arcellx
$67.59
-4.7%
$64.75
$47.86
$107.37
$3.72B0.28606,680 shs538,450 shs
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$20.62
-5.0%
$24.23
$20.43
$53.96
$972.01M0.72500,236 shs430,242 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$47.63
-1.9%
$48.83
$29.02
$58.38
$3.78B0.5876,850 shs628,561 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$33.76
-0.8%
$30.98
$21.51
$56.00
$4.07B0.911.42 million shs2.72 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcellx, Inc. stock logo
ACLX
Arcellx
0.00%-2.02%+5.91%+8.98%+3.18%
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.00%-4.80%-18.63%-11.69%-47.69%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
0.00%-1.89%-5.55%+0.51%+39.31%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
0.00%+7.34%+15.14%+26.63%-25.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcellx, Inc. stock logo
ACLX
Arcellx
2.5528 of 5 stars
3.52.00.00.02.92.50.0
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4.2963 of 5 stars
3.12.00.03.71.84.21.3
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
4.3345 of 5 stars
4.31.00.04.42.10.81.3
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.4124 of 5 stars
4.50.00.00.03.20.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcellx, Inc. stock logo
ACLX
Arcellx
3.07
Buy$111.2364.57% Upside
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2.25
Hold$32.3356.81% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.67
Moderate Buy$65.0036.47% Upside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.06
Buy$66.3596.54% Upside

Current Analyst Ratings Breakdown

Latest AMPH, RNA, PTCT, and ACLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$70.00
7/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$55.00
6/27/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$96.00
6/24/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$50.00
6/17/2025
Arcellx, Inc. stock logo
ACLX
Arcellx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$110.00
6/17/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
6/17/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
6/16/2025
Arcellx, Inc. stock logo
ACLX
Arcellx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00
6/11/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy$65.00
6/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$70.00 ➝ $75.00
6/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcellx, Inc. stock logo
ACLX
Arcellx
$107.94M34.51N/AN/A$8.41 per share8.04
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$731.97M1.33$5.00 per share4.12$15.23 per share1.35
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$806.78M4.68N/AN/A($14.24) per share-3.34
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$10.90M373.28N/AN/A$11.94 per share2.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcellx, Inc. stock logo
ACLX
Arcellx
-$107.35M-$2.99N/AN/AN/A-211.46%-35.27%-22.73%8/14/2025 (Estimated)
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$159.52M$2.767.476.275.3719.38%22.20%10.40%8/6/2025 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$363.30M$6.517.32N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)

Latest AMPH, RNA, PTCT, and ACLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Arcellx, Inc. stock logo
ACLX
Arcellx
-$1.03N/AN/AN/AN/AN/A
8/14/2025Q2 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$1.07N/AN/AN/AN/AN/A
8/8/2025Q2 2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$0.93N/AN/AN/A$1.61 millionN/A
8/6/2025Q2 2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.71N/AN/AN/A$173.42 millionN/A
5/8/2025Q1 2025
Arcellx, Inc. stock logo
ACLX
Arcellx
-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million
5/8/2025Q1 2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million
5/6/2025Q1 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.85$10.04+$9.19N/A$437.16 million$1.18 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcellx, Inc. stock logo
ACLX
Arcellx
N/AN/AN/AN/AN/A
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcellx, Inc. stock logo
ACLX
Arcellx
N/A
4.93
4.93
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.80
2.95
2.02
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.89
3.85
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
16.91
16.91

Institutional Ownership

CompanyInstitutional Ownership
Arcellx, Inc. stock logo
ACLX
Arcellx
96.03%
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Arcellx, Inc. stock logo
ACLX
Arcellx
8.35%
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
27.50%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.50%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcellx, Inc. stock logo
ACLX
Arcellx
8055.11 million50.51 millionOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2,02847.14 million34.18 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41079.26 million74.90 millionOptionable
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
190120.52 million115.90 millionOptionable

Recent News About These Companies

Avidity Biosciences, Inc. (RNA) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arcellx stock logo

Arcellx NASDAQ:ACLX

$67.59 -3.36 (-4.74%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$67.58 -0.01 (-0.01%)
As of 07/18/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$20.62 -1.08 (-4.98%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$21.04 +0.42 (+2.04%)
As of 07/18/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$47.63 -0.90 (-1.85%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$47.62 -0.01 (-0.02%)
As of 07/18/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$33.76 -0.28 (-0.82%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$33.95 +0.19 (+0.56%)
As of 07/18/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.